Page 1

Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights -Completed initial public offering for $ 92.7 million of gross proceeds - - Clinical proof - of - concept data for RLYB211 for the prevention of FNAIT was presented at the ISTH Virtual Congress ; Additional Phase 1/2 data expected in 4Q 2021- - On - track to initiate Phase 1 studies of RLYB212 , in development for the prevention of FNAIT , and RLYB116 , in development for the treatment of patients with PNH and gMG , in 1Q 2022 - New Haven , Conn . -- September 9 , 2021 -- Rallybio Corporation ( Nasdaq : RLYB ) , a clinical - stage biotechnology company committed to identifying and accelerating the development of life - transforming therapies for patients with severe and rare diseases , today reported its financial results for the second quarter ended June 30 , 2021 and provided an update on recent corporate developments . " Since our founding in 2018 , Rallybio has made consistent progress towards achieving our mission to truly transform the lives of patients with severe and rare diseases . With a tremendous team , we have now built a diversified portfolio of five programs , and we continue to work expeditiously to advance our pipeline , " said Martin Mackay , Ph.D. , Chief Executive Officer of Rallybio . " Following the closing of our initial public offering in early August , we are operating from a position of financial strength , and we are poised to build on this momentum in the months ahead , with additional Phase 1/2 data for RLYB211 expected before year end , and the initiation of Phase 1 studies of RLYB212 and RLYB116 both planned for the first quarter of 2022. " Rallybio's current pipeline is focused on addressing diseases in the areas of hematology , immuno - inflammation , maternal fetal health , and metabolic disorders . Recent 2021 Business Highlights : • • In July 2021 , Phase 1/2 clinical proof - of - concept data for RLYB211 was presented at the International Society on Thrombosis and Haemostasis ( ISTH ) 2021 Virtual Congress . RLYB211 is a polyclonal anti - HPA - 1a antibody in development for the prevention of fetal and neonatal alloimmune thrombocytopenia ( FNAIT ) . The data presented at ISTH demonstrated the ability of an anti - HPA - 1a antibody to rapidly and completely clear HPA - 1a positive platelets from the circulation of HPA - 1a negative participants . Based on these results , Rallybio believes that administration of an anti - HPA - 1a antibody could be a viable approach for the prevention of FNAIT . In addition , treatment with RLYB211 was safe and well tolerated , and no serious adverse events were observed . The poster presentation can be accessed on Rallybio's website here . In August 2021 , Rallybio closed its initial public offering ( IPO ) of 7,130,000 shares of common stock at a public offering price of $ 13.00 per share . The aggregate gross proceeds to Rallybio from the offering were approximately $ 92.7 million , before deducting underwriting discounts , commissions and other offering expenses . Upcoming Milestones : • Rallybio is on - track to initiate a natural history study of FNAIT in the third quarter of 2021 . . • • Rallybio plans to announce additional clinical data from the ongoing Phase 1/2 clinical trial of RLYB211 in the fourth quarter of 2021 . Rallybio remains on - track to initiate a Phase 1 study of RLYB212 in the first quarter of 2022. RLYB212 is a monoclonal anti - HPA - 1a antibody in development for the prevention of FNAIT . Rallybio remains on - track to initiate a Phase 1 study of RLYB116 in the first quarter of 2022. RLYB116 is a novel , potentially long - acting , subcutaneously administered inhibitor of complement factor 5 , or C5 , in development for the treatment of patients with paroxysmal nocturnal hemoglobinuria ( PNH ) and generalized Myasthenia Gravis ( gMG ) .